HGCapital
Hg Capital
Hg Capital
6200000
2021
20210729
competition-related offences
Warning: Undefined array key "offence_type" in /usr/home/goodjobsfirst/public_html/Live-UK-ViolationTracker/function.php on line 348
The Competition and Markets Authority (CMA) found that from 2009 until 2017 the pharmaceutical company Advanz charged excessive and unfair prices for supplying liothyronine tablets which are used to treat thyroid hormone deficiency. The agency also fined two private equity firms, HGCapital and Cinven, that previously owned parts of the business.
UK-CMA
Competition and Markets Authority
Germany
privately held
private equity (including portfolio companies)
private equity (including portfolio companies)
https://www.gov.uk/government/news/cma-fines-pharma-firm-over-pricing-of-crucial-thyroid-drug
HGCapital’s fine was reduced to £6.2 million on appeal in 2023
UK21-96060
1